International Journal of Molecular Sciences (Aug 2024)

Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate Cancer

  • Mutlay Sayan,
  • Yetkin Tuac,
  • Mahmut Akgul,
  • Samet Kucukcolak,
  • Elza Tjio,
  • Dilara Akbulut,
  • Luke W. Chen,
  • David D. Yang,
  • Shalini Moningi,
  • Jonathan E. Leeman,
  • Peter F. Orio,
  • Paul L. Nguyen,
  • Anthony V. D’Amico,
  • Cagdas Aktan

DOI
https://doi.org/10.3390/ijms25168913
Journal volume & issue
Vol. 25, no. 16
p. 8913

Abstract

Read online

Prostate cancer has substantial heterogeneity in clinical outcomes and therapeutic responses, posing challenges in predicting disease progression and tailoring treatment strategies. Recent studies have highlighted the potential prognostic value of evaluating the tumor microenvironment, including the presence of a histologically overt stromal response (HOST-response) characterized by peri-glandular stromal changes and architectural distortions. This retrospective study examined patient records from The Cancer Genome Atlas database to identify genomic alterations associated with the HOST-response in prostate cancer. Among 348 patients who underwent radical prostatectomy, 160 (45.98%) were identified as having a HOST-response. A gene expression analysis revealed 1263 genes with significantly higher expression in patients with a HOST-response. A protein–protein interaction network analysis identified seven hub genes (KIF2C, CENPA, CDC20, UBE2C, ESPL1, KIF23, and PLK1) highly interconnected in the network. A functional enrichment analysis revealed alterations in the cell division, cytoskeletal organization, cytokinesis, and interleukin-16 signaling pathways in patients with a HOST-response, suggesting dysregulated proliferation and inflammation. The distinct molecular signature associated with the HOST-response provides insights into the tumor–stroma interactions driving adverse outcomes and potential targets for tailored therapeutic interventions in this subset of patients with prostate cancer.

Keywords